

# NULISAqpcr™ BD-pTau217 Assay

## From Brain to Blood. Quantify What Matters. Achieve a new level of precision with brain-specific detection.

BD-pTau217 is a brain-derived phosphorylated tau protein isoform that serves as a highly specific biomarker for neurodegenerative disease. Tau proteins are distributed throughout the body, but only a fraction found in blood originates from the brain, with the majority secreted by peripheral organs. Elevated levels of BD-pTau217 in cerebrospinal fluid (CSF) are a hallmark of Alzheimer's Disease (AD), while increased blood pTau217—primarily

from peripheral sources is associated with other neurodegenerative diseases. The NULISAqpcr BD-pTau217 Assay precisely detects brain-derived pTau217 in either blood or cerebral spinal fluid using only 10 µL of biological sample. The analytical performance of the NULISAqpcr BD-pTau217 Assay has been rigorously validated to ensure the highest level of confidence in your results.

### Precise Quantitation

Absolute quantitation of plasma-based brain-derived pTau217.

### CNS Specificity

Uniquely specific to the low molecular weight pTau217 isoform originating from the central nervous system.

### Clinical Research Utility

Supports clinical research and longitudinal studies with CV<10%.


### Automated Workflow

Fully automated workflows with under 30 minutes hands-on time using the ARGO HT system.

### Flexible Sample Collection


Established protocols for blood, plasma, and dried plasma/blood spot collection devices.

In blood, Tau comes from brain and periphery.



- ▲ 20% come from the brain and indicative of accumulation of Tau in the brain
- 80% are secreted by peripheral organs and not reflective of Tau status in the brain

In CSF, 100% of all Tau comes from the brain.



**Specific detection of brain-derived pTau217 for neurodegenerative disease insights.** In neurodegenerative conditions marked by Tau accumulation, protein sources may originate from either brain or peripheral tissues. For Alzheimer's disease, when detecting pTau217 from blood or plasma it is critical to distinctly detect brain originated pTau217 versus that originated from peripheral tissues.



Learn more about NULISA and it's utilization in CNS disease research.

SAPIENT



# NULISAqpcr™ BD-pTau217 Assay


## More Power to Detect with Brain Specificity

Detect elevated levels of brain-derived pTau217 in plasma from Alzheimer's disease samples.


## Quantify More with fg/mL Sensitivity

A7-point standard curve enables absolute quantitation.

Alzheimer's Disease v. Normal Plasma Samples



BD-pTau=p-217 (4PL curve fit)



The NULISAqpcr BD-pTau217 Assay is a **first-of-its-kind offering as the only brain-derived single-plex solution available**, setting a new benchmark for precision and CNS specificity in neurodegenerative disease research.



Brought to you by Sapiient, an Alamar Certified Service Provider for NULISA™ panels and assays

Tap our deep expertise in Alamar's technologies and in multi-omics data and insight generation to obtain robust measures for the most relevant cytokine and chemokine inflammation targets.

**Request services:** [sapiient.bio/nulisa](https://sapiient.bio/nulisa) | [discover@sapiient.bio](mailto:discover@sapiient.bio) | 858.290.7010

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

©2025 Alamar Biosciences, Inc. All rights reserved. Alamar, NULISA, NULISAqpcr and ARGO are trademarks of Alamar Biosciences, Inc. All other trademarks and/or service marks not owned by Alamar that appear are the property of their respective owners. M1037-1025.3

